RECURRENT MALIGNANT SOLID NEOPLASM
Clinical trials for RECURRENT MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: drug targets unique genetic flaw
Disease control OngoingThis study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Early trial for young cancer patients halted before starting
Disease control TerminatedThis early-phase study aimed to test the safety and effectiveness of a two-drug immunotherapy combination (nivolumab and ipilimumab) in children, teens, and young adults. It was specifically for patients whose cancers had returned or stopped responding to standard treatments and …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New cancer drug cocktail aims to shrink tough tumors
Disease control TerminatedThis early-phase trial is testing the safety and best dose of a new oral drug, ZEN003694, when given with standard immunotherapy drugs (nivolumab with or without ipilimumab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for tough cancers: scientists test Triple-Threat drug cocktail in kids
Disease control OngoingThis early-stage trial is testing a new combination of three drugs—dasatinib, temsirolimus, and cyclophosphamide—to treat advanced solid tumors that have come back or stopped responding to other treatments. The main goal is to find the safest dose and understand the side effects.…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat cancers: drug trial targets specific genetic flaw
Disease control OngoingThis study is testing whether the drug olaparib can help control advanced cancers that have a specific genetic change (IDH1 or IDH2 mutation) and have stopped responding to standard treatments. It is enrolling adults with certain brain tumors, bile duct cancer, or other solid tum…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Targeted drug trial offers hope for kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing a targeted drug called selpercatinib in children and young adults with advanced or returning cancers that have specific changes in a gene called RET. The goal is to see if the drug can shrink tumors and control the cancer's growth. Participants take the drug…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope pill tested for kids with tough cancers
Disease control OngoingThis study is testing whether a pill called cabozantinib can help control rare cancers that have come back or stopped responding to other treatments in children and young adults. It includes patients with sarcomas, Wilms tumor, and other rare tumors. The drug aims to slow or stop…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for kids with tough cancers: trial tests precision medicine
Disease control OngoingThis study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Cancer trial matches drugs to your Tumor's DNA
Disease control OngoingThis large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New immune attack on rare, aggressive cancers
Disease control OngoingThis study is testing a combination of two immunotherapy drugs, tiragolumab and atezolizumab, for children and adults with rare, aggressive cancers that have come back or stopped responding to standard treatments. These cancers are missing specific genes (SMARCB1 or SMARCA4). The…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for kids with tough cancers: treatment guided by tumor genetics
Disease control OngoingThis study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for kids with tough cancers: drug targets genetic flaw
Disease control OngoingThis study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New hope for kids with tough cancers: experimental pill enters trial
Disease control OngoingThis study is testing a new oral drug called Elimusertib in children and young adults whose solid tumors have come back or stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can shrink tumors, particularly in certain types of…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Scientists test new two- and Three-Drug cocktails against tough cancers
Disease control OngoingThis early-phase study is testing the safety and best doses of combining the cancer drug copanlisib with immunotherapy drugs (nivolumab alone or with ipilimumab). It involves 64 adults with advanced solid tumors or lymphoma that have progressed after standard treatments. The goal…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:52 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
Cancer's hidden cost: new program aims to ease financial pain for patients
Symptom relief OngoingThis study tests whether a financial counseling program can reduce money problems and stress for people with cancer and their partners. It compares two groups: one gets basic financial education, and the other gets that plus monthly meetings with a financial counselor. The goal i…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated Apr 01, 2026 18:11 UTC
-
Can a sugar pill you know is fake ease cancer fatigue?
Symptom relief OngoingThis study is testing if an 'open-label' placebo—a sugar pill that patients know contains no medicine—can help reduce severe fatigue in people with advanced cancer. About 100 participants with significant fatigue were randomly assigned to either start taking the placebo pills rig…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 01, 2026 14:42 UTC
-
New combo therapy aims to fight the exhausting fatigue of advanced cancer
Symptom relief OngoingThis study is testing whether a combination of home-based exercise and a short course of a steroid medication (dexamethasone) can help reduce severe fatigue in people with advanced cancer. The trial involves 99 participants who will be randomly assigned to do exercise with either…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 01, 2026 14:41 UTC
-
New combo therapy aims to fight debilitating cancer fatigue
Symptom relief OngoingThis study is testing whether a drug called anamorelin, combined with a home exercise program and nutritional counseling, can help reduce severe fatigue in people with advanced, incurable solid tumors. Participants take the drug daily for 6 weeks while following the exercise and …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 01, 2026 14:41 UTC
-
Phone support study aims to ease burden for cancer patients and families
Symptom relief OngoingThis study is testing two different ways to help cancer clinics provide a phone-based support program called ENABLE to patients with advanced cancer and their caregivers. The program focuses on improving quality of life by helping with stress, symptoms, communication, and plannin…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Mar 04, 2026 15:29 UTC
-
Cancer experts team up to crack genetic code for better treatments
Knowledge-focused OngoingThis study is testing whether having a team of cancer genetics experts review a patient's tumor test results helps doctors choose more effective treatments. It compares the usual approach where doctors review results alone against having a special 'genomic tumor board' provide ex…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Can they hear us? brain wave study seeks answers for families of dying patients
Knowledge-focused TerminatedThis study uses brain wave monitoring to understand if cancer patients who appear completely unresponsive near the end of life can still hear or understand words. Researchers will measure brain activity in response to speech and other stimuli in 30 patients. The goal is to provid…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
The hidden burden: how Cancer's weight loss wears down patients and families
Knowledge-focused OngoingThis study aims to understand how often advanced cancer patients experience severe weight loss and loss of appetite, a condition called cachexia. Researchers are also measuring the emotional and psychological stress this causes for both the patients and their primary family careg…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC